Seroatlas · Human Serome Atlas

SART3

Spliceosome associated factor 3, U4/U6 recycling protein

Also known as: KIAA0156, p110, RP11-13G14, SART3_HUMAN, TIP110

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q15020
Gene: SART3
Ensembl: ENSG00000075856
Chromosome: 12
Canonical length: 963 aa
Protein class: Human disease related genes, Plasma proteins, Predicted intracellular proteins
Subcellular location: Nucleoplasm

OverviewNCBI Gene

The protein encoded by this gene is an RNA-binding nuclear protein that is a tumor-rejection antigen. This antigen possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in cancer patients and may be useful for specific immunotherapy. This gene product is found to be an important cellular factor for HIV-1 gene expression and viral replication. It also associates transiently with U6 and U4/U6 snRNPs during the recycling phase of the spliceosome cycle. This encoded protein is thought to be involved in the regulation of mRNA splicing. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

963 residues, UniProt reviewed canonical sequence.

>Q15020|SART3
     1  MATAAETSAS EPEAESKAGP KADGEEDEVK AARTRRKVLS RAVAAATYKT MGPAWDQQEE
    61  GVSESDGDEY AMASSAESSP GEYEWEYDEE EEKNQLEIER LEEQLSINVY DYNCHVDLIR
   121  LLRLEGELTK VRMARQKMSE IFPLTEELWL EWLHDEISMA QDGLDREHVY DLFEKAVKDY
   181  ICPNIWLEYG QYSVGGIGQK GGLEKVRSVF ERALSSVGLH MTKGLALWEA YREFESAIVE
   241  AARLEKVHSL FRRQLAIPLY DMEATFAEYE EWSEDPIPES VIQNYNKALQ QLEKYKPYEE
   301  ALLQAEAPRL AEYQAYIDFE MKIGDPARIQ LIFERALVEN CLVPDLWIRY SQYLDRQLKV
   361  KDLVLSVHNR AIRNCPWTVA LWSRYLLAME RHGVDHQVIS VTFEKALNAG FIQATDYVEI
   421  WQAYLDYLRR RVDFKQDSSK ELEELRAAFT RALEYLKQEV EERFNESGDP SCVIMQNWAR
   481  IEARLCNNMQ KARELWDSIM TRGNAKYANM WLEYYNLERA HGDTQHCRKA LHRAVQCTSD
   541  YPEHVCEVLL TMERTEGSLE DWDIAVQKTE TRLARVNEQR MKAAEKEAAL VQQEEEKAEQ
   601  RKRARAEKKA LKKKKKIRGP EKRGADEDDE KEWGDDEEEQ PSKRRRVENS IPAAGETQNV
   661  EVAAGPAGKC AAVDVEPPSK QKEKAASLKR DMPKVLHDSS KDSITVFVSN LPYSMQEPDT
   721  KLRPLFEACG EVVQIRPIFS NRGDFRGYCY VEFKEEKSAL QALEMDRKSV EGRPMFVSPC
   781  VDKSKNPDFK VFRYSTSLEK HKLFISGLPF SCTKEELEEI CKAHGTVKDL RLVTNRAGKP
   841  KGLAYVEYEN ESQASQAVMK MDGMTIKENI IKVAISNPPQ RKVPEKPETR KAPGGPMLLP
   901  QTYGARGKGR TQLSLLPRAL QRPSAAAPQA ENGPAAAPAV AAPAATEAPK MSNADFAKLF
   961  LRK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SART3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.4
Highest tissue expression: 25 nTPM

Expression across tissuesHPA

Tissue

cerebellum: 25 nTPM
lymph node: 25 nTPM
bone marrow: 24 nTPM
thymus: 24 nTPM
tonsil: 22 nTPM
spleen: 20 nTPM

Single-cell type

late primary spermatocytes: 82 nCPM
erythrocyte progenitors: 68 nCPM
gastric progenitor cells: 65 nCPM
megakaryocytes: 62 nCPM
megakaryocyte progenitors: 60 nCPM
corticotrophs: 56 nCPM

Immune cell

T-reg: 11 nTPM
MAIT T-cell: 9.9 nTPM
naive CD4 T-cell: 9.4 nTPM
myeloid DC: 9.1 nTPM
NK-cell: 8.6 nTPM
gdT-cell: 8.4 nTPM

Brain region

cerebellum: 34 nTPM
white matter: 31 nTPM
hypothalamus: 28 nTPM
cerebral cortex: 26 nTPM
basal ganglia: 26 nTPM
thalamus: 26 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SART3.

Disease | GeneticClinVar

8 pathogenic / likely-pathogenic of 164 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Intellectual disability, Neurodevelopmental defects and Developmental delay with 46,XY gonadal dysgenesis

Disease | ImmuneIEDB

Conditions an epitope on SART3 was assayed in.

prostate cancer B and T cell
castration-resistant prostate carcinoma B and T cell
prostate adenocarcinoma B and T cell
cancer B and T cell
biliary tract cancer B and T cell
esophageal cancer B and T cell
carcinoma B and T cell
Her2-receptor negative breast cancer B and T cell
colorectal cancer B and T cell
Her2-receptor positive breast cancer B and T cell
synovial sarcoma B and T cell
prostatic urethral cancer B and T cell
pancreatic carcinoma B cell
lung small cell carcinoma B cell
adult hepatocellular carcinoma B cell
triple-receptor negative breast cancer B and T cell
hematologic cancer B cell
hepatocellular carcinoma B cell
cervical cancer B and T cell
gastric adenocarcinoma B and T cell

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.28
gnomAD pLI: 1
gnomAD missense Z: 0.81
DepMap mean gene effect: -1.81
DepMap dependency class: pan

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

RNA recognition motif domain
HAT (Half-A-TPR) repeat
Tetratricopeptide-like helical domain superfamily
Nucleotide-binding alpha-beta plait domain superfamily
RNA-binding domain superfamily
PRP39, C-terminal HAT repeat
RNA recognition motif
PRP39 N-terminal HAT repeat
PRP39 C-terminal HAT repeat
LSM-interacting domain
SART3, RNA recognition motif 1
SART3, RNA recognition motif 2
Lsm interaction motif
LSM-interacting associated unstructured

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SART3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SART3 as an antibody target. Whether an autoantibody or antibody against SART3 could matter depends on whether native SART3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SART3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label SART3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...